It’s a big day for ASX-listed Opthea, an eye therapies developer...

It’s a big day for ASX-listed Opthea, an eye therapies developer with a near $500 million market capitalisation.Street Talk. Louie DouvisThe company is in front of investors seeking a $US70 million equity injection via broker MST, which it needs to secure as part of a bigger $US240 million funding deal.Opthea has told investors that two lenders, Carlyle and ABW, will tip $US120 million into the company, with an option to increase by another $US50 million.Their funds would be used to help Opthea get market approval for one of its mooted products, OPT-302, and the financiers would receive success payments if it happened.However, the Carlyle/ABW transaction was conditional on Opthea raising its $US70 million equity.Broker MST kicked off a two-tranche placement on Thursday morning, while Jefferies was also on board for the US leg of the raising.more to come

PER AFR